» Articles » PMID: 36722313

Quercetin Prevents Osteoarthritis Progression Possibly Via Regulation of Local and Systemic Inflammatory Cascades

Overview
Journal J Cell Mol Med
Date 2023 Feb 1
PMID 36722313
Authors
Affiliations
Soon will be listed here.
Abstract

Due to the lack of effective treatments, osteoarthritis (OA) remains a challenge for clinicians. Quercetin, a bioflavonoid, has shown potent anti-inflammatory effects. However, its effect on preventing OA progression and the underlying mechanisms are still unclear. In this study, Sprague-Dawley male rats were divided into five groups: control group, OA group (monosodium iodoacetate intra-articular injection), and three quercetin-treated groups. Quercetin-treated groups were treated with intragastric quercetin once a day for 28 days. Gross observation and histopathological analysis showed cartilage degradation and matrix loss in the OA group. High-dose quercetin-group joints showed failure in OA progression. High-dose quercetin inhibited the OA-induced expression of MMP-3, MMP-13, ADAMTS4, and ADAMTS5 and promoted the OA-reduced expression of aggrecan and collagen II. Levels of most inflammatory cytokines and growth factors tested in synovial fluid and serum were upregulated in the OA group and these increases were reversed by high-dose quercetin. Similarly, subchondral trabecular bone was degraded in the OA group and this effect was reversed in the high-dose quercetin group. Our findings indicate that quercetin has a protective effect against OA development and progression possibly via maintaining the inflammatory cascade homeostasis. Therefore, quercetin could be a potential therapeutic agent to prevent OA progression in risk groups.

Citing Articles

Integrating network pharmacology and experimental verification to explore the pharmacological mechanisms of phlorizin against osteoarthritis.

Yao Y, Zhong Q, Zhong Y, Gao Z, Zhou B, Lu C Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):903-918.

PMID: 39085510 DOI: 10.1007/s00210-024-03324-z.


Quercetin Modulates Ferroptosis via the SIRT1/Nrf-2/HO-1 Pathway and Attenuates Cartilage Destruction in an Osteoarthritis Rat Model.

Ruan H, Zhu T, Wang T, Guo Y, Liu Y, Zheng J Int J Mol Sci. 2024; 25(13).

PMID: 39000568 PMC: 11242395. DOI: 10.3390/ijms25137461.


Quercetin through miR-147-5p/Clip3 axis reducing Th17 cell differentiation to alleviate periodontitis.

An Y, Zhao R, Liu W, Wei C, Jin L, Zhang M Regen Ther. 2024; 27:496-505.

PMID: 38756701 PMC: 11096707. DOI: 10.1016/j.reth.2024.04.016.


Quercetin attenuates Pseudomonas aeruginosa-induced acute lung inflammation by inhibiting PI3K/AKT/NF-κB signaling pathway.

Jia X, Gu M, Dai J, Wang J, Zhang Y, Pang Z Inflammopharmacology. 2024; 32(2):1059-1076.

PMID: 38310155 DOI: 10.1007/s10787-023-01416-5.


Osteoclasts and osteoarthritis: Novel intervention targets and therapeutic potentials during aging.

Wang H, Yuan T, Wang Y, Liu C, Li D, Li Z Aging Cell. 2024; 23(4):e14092.

PMID: 38287696 PMC: 11019147. DOI: 10.1111/acel.14092.


References
1.
Perotto J, de Alcantara Camejo F, Doetzer A, Almeida L, Azevedo M, Olandoski M . Expression of MMP-13 in human temporomandibular joint disc derangement and osteoarthritis. Cranio. 2017; 36(3):161-166. DOI: 10.1080/08869634.2017.1315511. View

2.
Huang X, Ni B, Xi Y, Chu X, Zhang R, You H . Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis. Aging (Albany NY). 2019; 11(24):12532-12545. PMC: 6949101. DOI: 10.18632/aging.102586. View

3.
Yasuda T . Cartilage destruction by matrix degradation products. Mod Rheumatol. 2006; 16(4):197-205. PMC: 2780665. DOI: 10.1007/s10165-006-0490-6. View

4.
Thomas A, Hubbard-Turner T, Wikstrom E, Palmieri-Smith R . Epidemiology of Posttraumatic Osteoarthritis. J Athl Train. 2016; 52(6):491-496. PMC: 5488839. DOI: 10.4085/1062-6050-51.5.08. View

5.
Mesaik A, Poh H, Bin O, Elawad I, Alsayed B . Anti-Inflammatory, Anti-Bacterial and Anti-Diarrhoeal Activity of Fruit Extract. Open Access Maced J Med Sci. 2018; 6(5):757-766. PMC: 5985874. DOI: 10.3889/oamjms.2018.168. View